Global miRNA/proteomic analyses identify miRNAs at 14q32 and 3p21, which contribute to features of chronic iron-exposed fallopian tube epithelial cells.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 03 2021
Historique:
received: 03 06 2020
accepted: 01 03 2021
entrez: 19 3 2021
pubmed: 20 3 2021
medline: 28 10 2021
Statut: epublish

Résumé

Malignant transformation of fallopian tube secretory epithelial cells (FTSECs) is a key contributing event to the development of high-grade serous ovarian carcinoma (HGSOC). Our recent findings implicate oncogenic transformative events in chronic iron-exposed FTSECs, including increased expression of oncogenic mediators, increased telomerase transcripts, and increased growth/migratory potential. Herein, we extend these studies by implementing an integrated transcriptomic and mass spectrometry-based proteomics approach to identify global miRNA and protein alterations, for which we also investigate a subset of these targets to iron-induced functional alterations. Proteomic analysis identified > 4500 proteins, of which 243 targets were differentially expressed. Sixty-five differentially expressed miRNAs were identified, of which 35 were associated with the "top" proteomic molecules (> fourfold change) identified by Ingenuity Pathway Analysis. Twenty of these 35 miRNAs are at the 14q32 locus (encoding a cluster of 54 miRNAs) with potential to be regulated by DNA methylation and histone deacetylation. At 14q32, miR-432-5p and miR-127-3p were ~ 100-fold downregulated whereas miR-138-5p was 16-fold downregulated at 3p21 in chronic iron-exposed FTSECs. Combinatorial treatment with methyltransferase and deacetylation inhibitors reversed expression of these miRNAs, suggesting chronic iron exposure alters miRNA expression via epigenetic alterations. In addition, PAX8, an important target in HGSOC and a potential miRNA target (from IPA) was epigenetically deregulated in iron-exposed FTSECs. However, both PAX8 and ALDH1A2 (another IPA-predicted target) were experimentally identified to be independently regulated by these miRNAs although TERT RNA was partially regulated by miR-138-5p. Interestingly, overexpression of miR-432-5p diminished cell numbers induced by long-term iron exposure in FTSECs. Collectively, our global profiling approaches uncovered patterns of miRNA and proteomic alterations that may be regulated by genome-wide epigenetic alterations and contribute to functional alterations induced by chronic iron exposure in FTSECs. This study may provide a platform to identify future biomarkers for early ovarian cancer detection and new targets for therapy.

Identifiants

pubmed: 33737539
doi: 10.1038/s41598-021-85342-y
pii: 10.1038/s41598-021-85342-y
pmc: PMC7973504
doi:

Substances chimiques

Biomarkers, Tumor 0
Ferric Compounds 0
MDS1 and EVI1 Complex Locus Protein 0
MECOM protein, human 0
MIRN138 microRNA, human 0
MicroRNAs 0
Proteome 0
Quaternary Ammonium Compounds 0
Vorinostat 58IFB293JI
Azacitidine M801H13NRU
ferric ammonium citrate UVP74NG1C5

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

6270

Subventions

Organisme : NCI NIH HHS
ID : R03 CA212696
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA178468
Pays : United States

Références

Int J Gynecol Pathol. 2013 Sep;32(5):444-53
pubmed: 23896717
J Ovarian Res. 2009 Aug 27;2(1):11
pubmed: 19712461
Oncol Lett. 2016 Nov;12(5):3633-3639
pubmed: 27900047
PLoS Biol. 2008 Jun 3;6(6):e135
pubmed: 18532878
Oncotarget. 2016 May 31;7(22):32785-95
pubmed: 27129161
Mol Cancer Res. 2018 Mar;16(3):390-402
pubmed: 29330288
BMC Cancer. 2016 Jan 21;16:33
pubmed: 26794413
Asian J Pharm Sci. 2020 Mar;15(2):237-251
pubmed: 32373202
Genes Genomics. 2018 Mar;40(3):243-251
pubmed: 29892795
Reprod Biol Endocrinol. 2014 Jul 06;12:60
pubmed: 24997727
Onco Targets Ther. 2018 Jan 31;11:599-608
pubmed: 29430185
Int J Mol Sci. 2016 Jan 20;17(1):
pubmed: 26805813
Oncotarget. 2016 Nov 8;7(45):72908-72922
pubmed: 27662660
Oncol Lett. 2017 Nov;14(5):5871-5875
pubmed: 29113220
Int J Oncol. 2013 May;42(5):1533-40
pubmed: 23467648
Mol Oncol. 2013 Jun;7(3):647-68
pubmed: 23517670
Int J Mol Sci. 2018 Jan 18;19(1):
pubmed: 29346265
Nutrients. 2013 Jul 10;5(7):2611-28
pubmed: 23846788
Br J Cancer. 2000 Jun;82(11):1801-7
pubmed: 10839294
J Biol Chem. 2017 Sep 22;292(38):15916-15926
pubmed: 28794155
Oncotarget. 2017 Nov 27;8(65):108316-108332
pubmed: 29312534
J Biochem. 2020 Jul 1;168(1):7-14
pubmed: 32003827
Int J Oncol. 2015 Mar;46(3):1089-98
pubmed: 25524880
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
J Exp Clin Cancer Res. 2013 Nov 22;32:96
pubmed: 24261995
Genome Res. 2000 Nov;10(11):1711-8
pubmed: 11076856
FEBS Lett. 2014 Dec 20;588(24):4665-71
pubmed: 25447521
Clin Rev Allergy Immunol. 2014 Oct;47(2):128-35
pubmed: 24362548
Int J Mol Sci. 2017 Apr 15;18(4):
pubmed: 28420141
Mol Aspects Med. 2020 Oct;75:100860
pubmed: 32340745
J Biomed Sci. 2010 Jul 29;17:64
pubmed: 20670406
Proteomics. 2019 Jun;19(11):e1800469
pubmed: 30980500
J Exp Clin Cancer Res. 2016 Apr 19;35:69
pubmed: 27095063
Cell Death Differ. 2010 Dec;17(12):1867-81
pubmed: 20508647
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Mol Cell Biol. 1998 Dec;18(12):6939-50
pubmed: 9819382
PLoS One. 2010 Sep 29;5(9):
pubmed: 20927380
Mol Cancer. 2017 Feb 16;16(1):40
pubmed: 28209178
Cell Metab. 2012 Jun 6;15(6):895-904
pubmed: 22633452
Oncol Rep. 2016 Nov;36(5):2563-2570
pubmed: 27571744
PLoS One. 2012;7(8):e43403
pubmed: 22952676
Genomics. 2007 Feb;89(2):280-90
pubmed: 17126526
Anticancer Res. 2015 Sep;35(9):4617-24
pubmed: 26254350
Womens Health (Lond). 2011 Sep;7(5):525-7
pubmed: 21879820
Oncol Lett. 2017 Jul;14(1):971-976
pubmed: 28693260
Eur J Neurosci. 2011 Jan;33(2):224-35
pubmed: 21070394
Cell Cycle. 2011 May 1;10(9):1378-84
pubmed: 21552008
J Clin Invest. 2019 Dec 2;129(12):5381-5399
pubmed: 31487270
J Am Chem Soc. 2014 Mar 26;136(12):4551-6
pubmed: 24592866
Oncogene. 2017 Jul 20;36(29):4089-4099
pubmed: 28319068
FASEB J. 2019 Feb;33(2):2460-2471
pubmed: 30277817
Cell Death Dis. 2013 Apr 18;4:e592
pubmed: 23598404
Cell Signal. 2019 Nov;63:109390
pubmed: 31419576
Oncogene. 2007 Nov 15;26(52):7283-301
pubmed: 17533367
Nat Rev Cancer. 2013 May;13(5):342-55
pubmed: 23594855
Nat Genet. 2003 Sep;35(1):97-102
pubmed: 12937418
Oncotarget. 2016 Aug 30;7(35):56200-56208
pubmed: 27621042
Int J Mol Sci. 2019 Jan 11;20(2):
pubmed: 30641920
Nat Protoc. 2012 Sep;7(9):1755-64
pubmed: 22936217
Exp Ther Med. 2017 Oct;14(4):3665-3673
pubmed: 29042962
Proteomics. 2018 Dec;18(23):e1800244
pubmed: 30267477
Mol Cancer Res. 2008 May;6(5):873-83
pubmed: 18505931
J Toxicol Sci. 2015 Jun;40(3):329-38
pubmed: 25972194
J Biol Chem. 2016 Sep 30;291(40):20827-20837
pubmed: 27497435
Cancer Sci. 2008 Feb;99(2):280-6
pubmed: 18201269
Epigenetics. 2009 Nov 16;4(8):587-92
pubmed: 19923923
Mod Pathol. 2011 Jun;24(6):751-64
pubmed: 21317881
Mod Pathol. 2013 Apr;26(4):553-62
pubmed: 23196794
Fertil Steril. 2002 Oct;78(4):712-8
pubmed: 12372445
Biophys Rep. 2018;4(4):178-188
pubmed: 30310855
FEBS Lett. 2018 Jun;592(12):2023-2031
pubmed: 29749098
Trends Cell Biol. 2016 Mar;26(3):165-176
pubmed: 26653790
Int J Cancer. 2008 Jul 1;123(1):8-13
pubmed: 18425818
Cell Oncol (Dordr). 2015 Jun;38(3):173-81
pubmed: 25875420
Oncogenesis. 2019 Aug 21;8(9):46
pubmed: 31434871
Oncotarget. 2016 Apr 12;7(15):20041-53
pubmed: 26942465
Am J Physiol Cell Physiol. 2016 May 1;310(9):C728-39
pubmed: 26911281
Cell Rep. 2012 Aug 30;2(2):270-82
pubmed: 22884366
Int J Mol Sci. 2018 Feb 03;19(2):
pubmed: 29401683
Genome Res. 2004 Sep;14(9):1741-8
pubmed: 15310658
Am J Cancer Res. 2019 Jun 01;9(6):1118-1126
pubmed: 31285946
Mol Cell Biol. 1993 Jul;13(7):4291-300
pubmed: 8321231
Diagnostics (Basel). 2019 Sep 14;9(3):
pubmed: 31540126
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17830-5
pubmed: 19004786
Onco Targets Ther. 2019 May 30;12:4129-4139
pubmed: 31239701
Annu Rev Genet. 2007;41:169-92
pubmed: 17608616
Onco Targets Ther. 2019 Jun 28;12:4869-4881
pubmed: 31388302
Oncol Lett. 2018 Mar;15(3):2735-2742
pubmed: 29434998
Diagn Cytopathol. 2011 Aug;39(8):567-74
pubmed: 20607683
Mol Cell Biol. 1991 May;11(5):2665-74
pubmed: 2017172
Mol Cancer. 2014 Feb 26;13:40
pubmed: 24571667
Int J Oncol. 2010 Jul;37(1):61-9
pubmed: 20514397
PLoS One. 2016 Aug 09;11(8):e0160780
pubmed: 27504971
Oncol Rep. 2017 Aug;38(2):1295-1302
pubmed: 28656304
Nucleic Acids Res. 2008 Oct;36(18):5727-35
pubmed: 18776219
Oncol Lett. 2019 Jun;17(6):5793-5802
pubmed: 31186806
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Arch Toxicol. 2016 Oct;90(10):2405-19
pubmed: 27557899
Cell Biol Int. 2017 Sep;41(9):1056-1064
pubmed: 28707774
Oncogene. 1994 Jun;9(6):1575-81
pubmed: 8183551
Hum Reprod. 2006 Nov;21(11):2810-6
pubmed: 16849816
Int J Mol Med. 2009 Jul;24(1):45-50
pubmed: 19513533
Toxicol Sci. 2013 Dec;136(2):402-12
pubmed: 24052562
Hum Mol Genet. 2007 Jun 1;16(11):1335-42
pubmed: 17412760
J Biol Chem. 2005 Sep 2;280(35):30712-22
pubmed: 16006653
Biol Open. 2019 Aug 1;8(8):
pubmed: 31371307
J Proteomics. 2020 May 30;220:103753
pubmed: 32200115
Mol Cancer. 2012 Jul 02;11:44
pubmed: 22747855
Cancer Res. 2019 Feb 1;79(3):650-662
pubmed: 30538122
PLoS One. 2011;6(8):e24099
pubmed: 21909380
Biochem Biophys Res Commun. 2019 Oct 29;519(1):166-171
pubmed: 31492495
Clin Transl Oncol. 2011 Feb;13(2):71-6
pubmed: 21324793
Ann Transl Med. 2016 Dec;4(24):518
pubmed: 28149880
Cancer Cell. 2013 Dec 9;24(6):751-65
pubmed: 24332043
Sci Rep. 2015 Apr 13;5:9650
pubmed: 25867965
Adv Drug Deliv Rev. 2014 Dec 15;79-80:184-92
pubmed: 25034878
Int J Gynecol Cancer. 2015 Mar;25(3):389-98
pubmed: 25594146
Ann Surg Oncol. 2013 May;20(5):1745-52
pubmed: 22752337
Epigenetics. 2011 Dec;6(12):1413-24
pubmed: 22139571
Cancer Res. 1997 Feb 1;57(3):513-5
pubmed: 9012483
Front Physiol. 2013 Feb 14;3:480
pubmed: 23420281
Am J Respir Crit Care Med. 2013 Feb 15;187(4):397-405
pubmed: 23306545
Nat Genet. 2008 Feb;40(2):237-42
pubmed: 18176563
J Hematol Oncol. 2013 Aug 19;6:60
pubmed: 23958394
Front Bioeng Biotechnol. 2016 Feb 12;4:12
pubmed: 26904541
Future Oncol. 2014 May;10(6):1027-48
pubmed: 24941988
Exp Ther Med. 2018 Sep;16(3):1629-1638
pubmed: 30186381
Acta Neuropathol Commun. 2019 Jul 5;7(1):107
pubmed: 31277703
Free Radic Biol Med. 2019 Mar;133:216-220
pubmed: 30040994
Epigenetics. 2014 Jan;9(1):142-51
pubmed: 24081307
Elife. 2019 May 03;8:
pubmed: 31050342
Cancer Biol Med. 2015 Dec;12(4):328-41
pubmed: 26779370
Stem Cells. 2009 Sep;27(9):2220-8
pubmed: 19544409
Asian Pac J Cancer Prev. 2013;14(6):3757-60
pubmed: 23886178
Oncol Rep. 2017 Aug;38(2):1067-1074
pubmed: 28677784
J Cell Physiol. 2020 Sep;235(9):6103-6112
pubmed: 31975381
PLoS Genet. 2020 Jun 4;16(6):e1008808
pubmed: 32497036
Gastroenterology. 2004 Nov;127(5 Suppl 1):S79-86
pubmed: 15508107
Oncotarget. 2017 Mar 14;8(11):17712-17725
pubmed: 27487123
Nat Commun. 2017 Oct 23;8(1):1093
pubmed: 29061967
Int J Clin Exp Pathol. 2017 Dec 01;10(12):11516-11525
pubmed: 31966507
Biol Chem. 2017 Aug 28;398(9):995-1007
pubmed: 28095368
Pharmaceuticals (Basel). 2018 Oct 22;11(4):
pubmed: 30360386
Gynecol Oncol. 2010 Aug 1;118(2):189-95
pubmed: 20462630
Genes Dis. 2018 Dec 31;6(1):16-24
pubmed: 30906828
Oncotarget. 2015 Feb 28;6(6):3540-52
pubmed: 25686838
J Proteomics. 2016 Jan 30;132:51-62
pubmed: 26585461
Oncogene. 2014 Oct 30;33(44):5173-82
pubmed: 24166498
Anticancer Res. 2011 Sep;31(9):2723-32
pubmed: 21868513
Medicine (Baltimore). 2019 Jul;98(29):e16193
pubmed: 31335671
BMC Genomics. 2019 Jun 17;20(1):503
pubmed: 31208318
Clin Cancer Res. 2008 Jan 1;14(1):32-40
pubmed: 18172249
Hepatology. 2014 Jan;59(1):202-15
pubmed: 23913442
Int J Med Sci. 2019 Oct 11;16(11):1480-1491
pubmed: 31673240
Front Cardiovasc Med. 2019 Aug 08;6:113
pubmed: 31440517
Oncotarget. 2017 Feb 7;8(6):9597-9607
pubmed: 28030816

Auteurs

Ravneet Chhabra (R)

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, 33620, USA.

Stephanie Rockfield (S)

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, 33620, USA.
Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA.

Jennifer Guergues (J)

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, 33620, USA.
Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 261 Mountain View Drive, Colchester, VT, 05446, USA.

Owen W Nadeau (OW)

Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 261 Mountain View Drive, Colchester, VT, 05446, USA.

Robert Hill (R)

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, 33620, USA.

Stanley M Stevens (SM)

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, 33620, USA.
Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 261 Mountain View Drive, Colchester, VT, 05446, USA.

Meera Nanjundan (M)

Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, 33620, USA. mnanjund@usf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH